World's Best Scientists 2026 revealed!
Richard D. Gelber

Richard D. Gelber

D-Index & Metrics

Medicine

D-Index
161
Citations
137489
World Ranking
732
National Ranking
415

Research.com Recognitions

  • 1993 - Fellow of the American Statistical Association (ASA)

Overview

Richard D. Gelber is affiliated with Harvard University in the United States. Their research spans multiple areas primarily within medicine and biochemistry, genetics, and molecular biology, with a focus on oncology and cancer-related studies.

Their work encompasses the following main fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specific areas of investigation within these fields include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

Richard D. Gelber's research topics cover a range of themes related to cancer and its treatment, such as:

  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Risks and Factors
  • Estrogen and related hormone effects
  • Monoclonal and Polyclonal Antibodies Research

They have co-authored extensively with the following researchers:

  • Martine Piccart (44 collaborations)
  • Marco Colleoni (33 collaborations)
  • Giuseppe Viale (29 collaborations)
  • Evandro de Azambuja (24 collaborations)
  • Aron Goldhirsch (21 collaborations)

The primary publication venues for Richard D. Gelber's work include:

  • Journal of Clinical Oncology (19 publications)
  • Cancer Research (14 publications)
  • Breast Cancer Research and Treatment (7 publications)
  • Annals of Oncology (5 publications)
  • The Breast (5 publications)

Recent notable papers authored or co-authored by Richard D. Gelber include:

  • "Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer," 2021, New England Journal of Medicine
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer," 2022, Annals of Oncology
  • "Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up," 2021, Journal of Clinical Oncology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials," 2021, The Lancet Oncology
  • "Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer," 2023, New England Journal of Medicine

Richard D. Gelber was awarded the status of Fellow of the American Statistical Association (ASA) in 1993.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

    Edward M. Connor;Rhoda S. Sperling;Richard Gelber;Pavel Kiselev

  • Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

    A. Goldhirsch;W.C. Wood;A.S. Coates;R.D. Gelber

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Reduction of maternal-infant transmission of human immunodeficiency virus 1 with zidovudine treatment

    Edward M. Connor;Rhoda S. Sperling;Richard Gelber;Pavel Kiselev

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood

    Steven E. Lipshultz;Steven D. Colan;Richard D. Gelber;Antonio R. Perez-Atayde

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    A. Goldhirsch;J. H. Glick;R. D. Gelber;A. S. Coates

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    Gunter von Minckwitz;Marion Procter;Evandro de Azambuja;Dimitrios Zardavas

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

    A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates

  • Analysis of survival by tumor response.

    James R. Anderson;Kevin C. Cain;Richard D. Gelber

  • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

    Lewis B. Silverman;Richard D. Gelber;Virginia Kimball Dalton;Barbara L. Asselin

Frequent Co-Authors

Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Alan S. Coates
Alan S. Coates University of Sydney
Karen N. Price
Karen N. Price Frontier Science Foundation
Giuseppe Viale
Giuseppe Viale University of Milan
Marco Colleoni
Marco Colleoni European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
Stephen E. Sallan
Stephen E. Sallan Harvard University
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
John F. Forbes
John F. Forbes University of Limerick

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready to commit to a traditional MD program, there are flexible online alternatives that can launch or advance a medical career. Online nursing programs offer students foundational knowledge and hands-on skills required for various clinical roles. These programs are ideal for both newcomers and those looking to shift into the medical field.

For practicing nurses aiming to deepen expertise and pursue advanced practice or research roles, online nursing PhD programs make doctoral education accessible and affordable. Meanwhile, the cheapest online RN to BSN programs provide a convenient path for registered nurses to earn a bachelor’s degree and open doors to higher-level positions.

If you hold a non-nursing bachelor’s degree but want to join the nursing profession, entry level MSN programs online offer accelerated routes to a master’s degree in nursing. These diverse pathways make it easier than ever to start or advance a healthcare career—without the need for traditional, on-campus education.

Best Scientists Citing Richard D. Gelber

Trending Scientists